Top of this page
Skip navigation, go straight to the content
UCB in brief
- A global biopharma leader focused on severe diseases, with operations in more than 40 countries and global revenue of more than €3.6 billion in 2007.
- The leader in allergy and epilepsy, with twelve new large and small molecules in the pipeline, spanning sixteen diseases, from Crohn’s and Parkinson’s disease to multiple sclerosis.
- A leader in antibody research, supported by proprietary chemistry and over 30 major R&D partners.
Contact our IR team
Our future potential
Roch Doliveux
UCB Chief Executive Officer
